The estimated Net Worth of Paul Burton is at least $91.1 Thousand dollars as of 4 November 2022. Paul Burton owns over 402 units of Moderna Inc stock worth over $91,118 and over the last 3 years Paul sold MRNA stock worth over $0.
Paul has made over 2 trades of the Moderna Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Paul exercised 402 units of MRNA stock worth $31,963 on 4 November 2022.
The largest trade Paul's ever made was exercising 1,609 units of Moderna Inc stock on 5 August 2022 worth over $312,436. On average, Paul trades about 402 units every 18 days since 2021. As of 4 November 2022 Paul still owns at least 1,146 units of Moderna Inc stock.
You can see the complete history of Paul Burton stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein, and Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: